Method Article

Preparation and Evaluation of Mouse Premature Ovarian Insufficiency Model

1.5K views

DOI:

10.3791/69000

September 19th, 2025

In This Article

Summary

This protocol delineates a method for constructing a premature ovarian insufficiency mouse model via cyclophosphamide injection. The model effectively, readily, and adaptably replicates the pathological progression of human premature ovarian insufficiency, demonstrating high reliability and cost-effectiveness.

Abstract

Premature ovarian insufficiency (POI) is a critical condition leading to female infertility, necessitating reliable animal models for mechanistic and therapeutic research. Here, we present a standardized protocol for establishing and evaluating a cyclophosphamide (CTX)-induced POI mouse model. Six-to-eight-week-old female mice with regular estrous cycles were selected and subjected to intraperitoneal CTX injections: an initial dose of 100 mg/kg on day 1, followed by daily doses of 20 mg/kg for the subsequent 14 days. Dynamic changes in estrous cycles were monitored via vaginal smear cytology with Wright staining. Serum levels of estradiol (E2), follicle-stimulating hormone (FSH), and anti-Müllerian hormone (AMH) were quantified using ELISA to assess endocrine alterations. Ovarian histopathology was evaluated through hematoxylin-eosin (H&E) staining of paraffin-embedded sections to quantify follicular atresia, while immunohistochemical analysis of cleaved caspase-3 was performed to detect granulosa cell apoptosis. Results demonstrated disrupted estrous cyclicity, significantly reduced E2 and AMH levels, elevated FSH concentrations, increased follicular atresia, and enhanced granulosa cell apoptosis in CTX-treated mice, confirming successful POI modeling. This model-building method can highly mimic the mechanism of chemotherapy-induced ovarian damage, presenting typical pathological features such as follicle reserve depletion and sex hormone disorders. It provides a reliable experimental platform for revealing the reproductive toxicity mechanism of chemotherapy, screening ovarian-protecting drugs, and optimizing fertility preservation strategies. Moreover, this model is relatively simple to operate, low-cost, and has a short production cycle, making it easy to carry out and popularize. The methodology aligns with the requirements of JoVE for visualizable, step-by-step experimental demonstrations.

Introduction

Premature ovarian insufficiency (POI), the most prevalent form of female reproductive aging disorder, not only severely compromises patients' physical and mental health through estrogen deficiency symptoms and reproductive dysfunction, but also elevates the risks of developing comorbidities, including fractures, autoimmune disorders, cardiovascular diseases, diabetes mellitus, etc.1. The development of efficient and safe therapeutic strategies has thus become a critically urgent priority in modern medicine. Given the limited availability of clinical samples, multifactorial etiology, and high ethical risks associated with POI research, the estab....

Access restricted. Please log in or start a trial to view this content.

Protocol

This protocol has been reviewed and approved by the Ethics Committee of Anhui Shendong Biotechnology Development Co., Ltd. (Ethics Number: SDLL202502281). This study adheres to the guidelines of the National Institutes of Health on the care and use of laboratory rodents in all animal experiment procedures. The female C57BL/6 mice used in this experiment were 6-8 weeks old and maintained under specific pathogen-free (SPF) conditions. As an inbred strain and a substrain of the C57 lineage, C57BL/6 mice are characterized by their black coat. Prior to experimentation, the mice were acclimatized for one week in the animal laboratory under controlled temperature and humidit....

Access restricted. Please log in or start a trial to view this content.

Results

The process of establishing the POI mouse model is illustrated in Figure 2. The body weight and estrous cycle of the mice were recorded starting from the first day of drug injection. After 15 days of CTX injection, the average body weight decline rate of the mice in the POI group (3.717% ± 1.463%) was significantly higher than that in the BLANK group (0.2526% ± 0.1469%) and the NS group (0.4305% ± 0.2494%) (p < 0.0001). There was no statistically significant difference in body we.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Premature ovarian insufficiency (POI) seriously affects women's physical health and quality of life, and its global prevalence is increasing year by year. However, at present, there is still a lack of safe and effective treatment methods for POI. Establishing a reliable and reproducible animal model is crucial for advancing research on POI. Clinically, the causes of POI are diverse, and chemotherapy drugs are important known pathogenic factors8. As an alkylating agent chemotherapy drug, CTX mainly.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to disclose.

Acknowledgements

The authors gratefully acknowledge the financial support received from the Wu Jieping Medical Foundation through its Clinical Research Special Funding Program (Grant No. 320.6750.17067). We also gratefully acknowledge the research platform and technical support that Anhui Shendong Biotechnology Development Co., Ltd provided.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
4% paraformaldehydeSangon Bioengineering Co., LtdA500684-0500
75% alcoholShandong Dexinkang Medical Technology Co., Ltd200603
Anhydrous ethanolBengbu Chemical Reagent Factory
Centrifuge tubesbiosharpBS-15-M
Cold tableQuanlin MedicalQL-LT20230003
Cotton ballsShandong Brilliance Co., Ltd20241008
CoverslipsJiangsu Shitai Experimental Equipment Co., Ltd80312-3412
CyclophosphamideBaxter Oncology GmbH3K645A
DehydratorHubei Xiaogan Haikuo Medical Technology Co., LtdKH-TS
Dyeing machineHubei Xiaogan Haikuo Medical Technology Co., LtdKH-S101 
EA50 staining solutionHubei Taikang Medical Equipment Co., LtdJ7EC20
Ear tag pliersShenzhen Ruiwode Life Science and TechnologyC22002-10
Efficient sectioning of paraffinTongxiang Hualing Wax Industry Co., Ltd20241018
Electric blast drying oven (oven)Shanghai Yuejin Medical Equipment Co., LtdHCZF-11
Electrically heated thermostatic water incubatorShanghai Yuejin Medical Equipment Co., LtdHSW-600
Embedding machinePrisstar Changzhou Medical Device Co., LtdPMB-A
Eosin stainSewell Biotechnology Co., LtdG1005-2
Hematoxylin differentiation solutionSewell Biotechnology Co., LtdG1039-500ML
Hematoxylin staining solutionSewell Biotechnology Co., LtdG1005-1
IsofluraneShandong Ante Animal Husbandry Technology Co., Ltd2024101501
microscopeAnhui Jiashang Biotechnology Co., LtdSQS-12P
Mouse anti-Mullerian hormone (AMH) ELISA kitHengyuan BiotechnologyHB1334-Mu
Mouse estradiol (E2) enzyme-linked immunoassay kitHengyuan BiotechnologyHB975-Mu
Mouse follicle-stimulating hormone (FSH) ELISA kitHengyuan BiotechnologyHB967-Mu
Neutral gumNanchang Yulu Experimental Equipment Co., Ltd240504
Pathological tissue bleaching apparatusPrisstar Changzhou Medical Device Co., LtdPHY-III
PBS bufferbiosharpBL302A
Pipette tipsbiosharpBS-10-T
PipettesDalong Medical Equipment Co., LtdYE213AT0257922
Rapid tissue dehydratorHubei Xiaogan Haikuo Medical Technology Co., LtdKH-TS
slicerGheddyYD-315
SlidesJiangsu Shitai Experimental Equipment Co., Ltd80312-3161
Smear machineHubei Taikang Medical Equipment Co., Ltd131001305
Sodium chloride injectionWuhan Binhu Shuanghe Pharmaceutical Co., Ltd240525K04
syringeJiangsu Zhiyu Medical Device Co., Ltd
Vibrating slicerShanghai Zhixin Instrument Co., LtdZQP-86
XyleneTianjin Kaitong Chemical Reagent Co., Ltd20240102

References

  1. Federici, S., et al. Primary ovarian insufficiency: update on clinical and genetic findings. Front Endocrinol. 15, 1464803(2024).
  2. Soleimani, R., Heytens, E., Darzynkiewicz, Z., Oktay, K. Mechanisms of chemotherap....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

POI Mouse ModelCyclophosphamide InductionEstrous Cycle MonitoringVaginal Smear CytologyWright StainingSerum Hormone AnalysisOvarian HistopathologyFollicular AtresiaGranulosa Cell Apoptosis

Related Articles